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EDITORIAL
Parenteral iron therapy: Beyond anaphylaxis
Controversies surrounding treatment with iron have
existed for the last several centuries. At the beginning
of the 18th century, the French physician Pierre Blaud
introduced “Blaud’s pill,” containing ferrous sulfate and
potassium carbonate for the treatment of chlorosis. In
the latter part of the 19th century, Gustav von Bunge,
a physiologic chemist, dismissed the effect of “Blaud’s
pill” as being placebo and wrote: “. . . If a poison is to be
used in such psychotherapy, it is better that one pick a
unabsorbable poison. In that case one should stick with
Blaud’s pills, or— better yet—bread pills. A good physi-
cian knows how to suggest without pills [1].” The use of
parenteral iron in the treatment of anemia in patients with
chronic kidney disease has become routine. However, re-
cent information related to the role of oxidants and iron
in the pathophysiology of disease has raised new concerns
about parenteral iron beyond the risk of anaphylaxis
[2–4].
In this issue of Kidney International, Zager, John-
son, and Hanson [5], using both in vitro and in vivo
models, demonstrate that there are differences in renal
tubular injury between parenteral iron preparations with
iron sucrose (Venofer) being the most toxic, followed by
iron gluconate (Ferrlecit), iron dextran (Infed), and iron
oligosaccharide as the least toxic. These differences in
toxicity paralleled the cellular uptake of iron. However,
it is important to note that the highest plasma concentra-
tions of malondialdehyde (MDA), a measure of oxidative
stress, were elicited by iron dextran.
This study, studies by others which indicate oxidant
stress imposed by parenteral iron [6, 7], and accumulating
evidence for the role of oxidants and iron in the patho-
physiology of a wide variety of diseases raise two broad
questions: does intravenous iron carry significant long-
term toxicity; and are there major differences in the long-
term toxicities between parenteral iron preparations? In
the patient with chronic kidney disease, the major con-
cerns of iron toxicity revolve around the progression of
kidney disease, infection and, most importantly, cardio-
vascular disease. Based on the study by Zager, Johnson,
and Hanson, it bears emphasis that the effect of par-
enteral iron preparations on different organ systems must
be considered separately.
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The study by Zager et al indicates that there are likely
to be major differences in acute renal tubular toxicity,
with iron preparations with iron sucrose having the high-
est uptake and renal toxicity. Support for the relevance
of this in human studies comes from Agarwal et al [8],
who administered iron sucrose to individuals with chronic
kidney disease and demonstrated increased enzymuria
and proteinuria. Although there is a large body of ex-
perimental evidence for the role of oxidants and iron in
progressive kidney disease [9], it is uncertain if acute in-
jury associated with parenteral administration of iron will
have long-term consequences. However, evidence that
repeated acute renal toxicity may lead to chronic tubu-
lointerstitial damage [10] suggests exercising prudence
in administering parenteral iron to patients early in the
course of chronic kidney disease. More specifically, the
choice of a particular iron preparation may be dictated
by the potential differences in the long-term toxicities to
different organ systems.
The second area of relevance of iron therapy and dis-
ease is infection. In another simple but telling study,
Zager et al [11] have demonstrated that administration
of parenteral iron in a model of experimental sepsis re-
sults in a profound increase in systemic oxidative stress,
in TNF-a release, and remarkably, a marked increase in
overall mortality. This study suggests that there is poten-
tial for parenteral iron therapy to exacerbate sepsis.
Finally, and perhaps most important, one has to con-
sider the importance of iron in atherosclerosis and car-
diovascular disease. It is generally accepted that there is
a major role of endothelial cell injury in the pathophysiol-
ogy of atherosclerosis. Despite conflicting epidemiologic
data, there is compelling mechanistic evidence for the
role of iron in endothelial cell injury and atherosclero-
sis, including the ability of iron to cause endothelial cell
damage, iron chelators preventing endothelial cell dam-
age by oxidized LDL, and the effect of iron chelators
in preventing endothelial cell dysfunction and vascular
smooth muscle cell proliferation [12].
There are three types of intravenous iron preparations
available in the United States, all of which have been
shown to increase oxidative stress in plasma after admin-
istration [6, 8, 13]. It is worth noting that in the study by
Zager, Johnson, and Hanson, although iron sucrose had
the most renal tubular toxicity, the highest oxidative stress
in plasma was imposed by iron dextran. The demonstra-
tion of increased oxidative stress in plasma with different
parenteral iron preparations may be relevant to vascular
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endothelial cell injury, accelerated atherosclerosis, and
cardiovascular morbid events in patients with chronic
kidney disease. There is supportive evidence that this in-
deed may be the case because it was reported that, in
patients with chronic kidney disease, iron therapy was
associated with markers of inflammation and oxidative
stress and increased carotid artery intima-media thick-
ness [14]. In addition, as reviewed previously [4], both
Collins and Besarab have demonstrated that administra-
tion of iron dextran is associated with an increase in car-
diac deaths for patients with end-stage kidney disease.
To date, the data suggest that all three intravenous iron
preparations pose a risk for endothelial cell injury and
atherosclerosis. These potential risks have to be weighed
against the benefits of treating anemia in patients with
chronic kidney disease. The benefits of targeting the
hematocrit to 33% to 36% for those with end-stage re-
nal disease include improved morbidity, mortality, and
quality of life [15]. Although the optimal target of ane-
mia therapy in patients with chronic kidney disease not
on dialysis has yet to be determined [16], the evidence
in favor of treating anemia is derived from small uncon-
trolled studies linking anemia with the development of
left ventricular hypertrophy, which is known to be asso-
ciated with an increased overall mortality. Clinical trials
are underway to examine the effect of anemia treatment
on cardiovascular events and mortality in this population.
To address the overall issue of long-term iron toxicity,
it will be necessary to compare the currently available
parenteral iron preparations with each other as well as
with other types of iron preparations such as dialysate
iron therapy [17] and heme iron polypeptide [18], an oral
iron product which may not contribute to oxidative stress.
Until such information is available it appears doubtful, in
our opinion, that the risk of intravenous iron therapy in
progressive kidney disease, infection, and cardiovascu-
lar disease outweighs the potential benefits of treating
anemia, at least for those patients with end-stage kidney
disease.
MUHAMMAD G. ALAM, MICHELLE W. KRAUSE,
and SUDHIR V. SHAH
Little Rock, Arkansas
Correspondence to Sudhir V. Shah, University of Arkansas for Medi-
cal Sciences, Department of Internal Medicine, Division of Nephrology,
4301 W. Markham St., Slot 501, Little Rock, AR 72205.
E-mail: shahsudhirv@uams.edu
REFERENCES
1. BEUTLER E: History of iron in medicine. Blood Cells Mol Dis 29:297–
308, 2002
2. SULLIVAN J: Iron therapy and cardiovascular disease. Kidney Int
69:S135–S137, 1999
3. FISHBANE S: Safety in iron management. Am J Kidney Dis 41:S18–
S26, 2003
4. BESARAB A, FRINAK S, YEE J: An indistinct balance: The safety and
efficacy of parenteral iron therapy. J Am Soc Nephrol 10:2029–2043,
1999
5. ZAGER RA, JOHNSON ACM, HANSON SY: Parenteral iron nephro-
toxicity: Potential mechanisms and consequences. Kidney Int 66:
2004
6. SALAHUDEEN AK, OLIVER B, BOWER JD, ROBERTS LJ II: Increase in
plasma esterified F2-isoprostanes following intravenous iron infu-
sion in patients on hemodialysis. Kidney Int 60:1525–1531, 2001
7. PARKKINEN J, VON BONSDORFF L, PELTONEN S, et al: Catalytically
active iron and bacterial growth in serum of haemodialysis patients
after i.v. iron-saccharate administration. Nephrol Dial Transplant
15:1827–1834, 2000
8. AGARWAL R, VASAVADA N, SACHS NG, et al: Oxidative stress and
renal injury with intravenous iron in patients with chronic kidney
disease. Kidney Int 66: 2004
9. SHAH SV: Role of iron in progressive renal disease. Am J Kidney
Dis 37:S30–S33, 2001
10. NATH KA, VERCELLOTTI GM, GRANDE JP, et al: Heme protein-
induced chronic renal inflammation: Suppressive effect of induced
heme oxygenase-1. Kidney Int 59:106–117, 2001
11. ZAGER RA, JOHNSON ACM, HANSON SY: Parenteral iron nephrotox-
icity: Potential mechanisms and consequences. Kidney Int 66:144–
156, 2004
12. SHAH SV, ALAM MG: Role of iron in atherosclerosis. Am J Kidney
Dis 41:80–83, 2003
13. ZANEN AL, ADRIAANSEN HJ, VAN BOMMEL EF, et al: Oversaturation
of transferrin after intravenous ferric gluconate (Ferrlecit(R)) in
haemodialysis patients. Nephrol Dial Transplant 11:820–824, 1996
14. DRUEKE T, WITKO-SARSAT V, MASSY Z, et al: Iron therapy, advanced
oxidation protein products, and carotid artery intima-media thick-
ness in end-stage renal disease. Circulation 106:2212–2217, 2002
15. MA JZ, EBBEN J, XIA H, COLLINS AJ: Hematocrit level and associ-
ated mortality in hemodialysis patients. J Am Soc Nephrol 10:610–
619, 1999
16. PEREIRA AA, SARNAK MJ: Anemia as a risk factor for cardiovascular
disease. Kidney Int 87:S32–S39, 2003
17. GUPTA A, AMIN NB, BESARAB A, et al: Dialysate iron therapy:
Infusion of soluble ferric pyrophosphate via the dialysate during
hemodialysis. Kidney Int 55:1891–1898, 1999
18. NISSENSON AR, BERNS JS, SAKIEWICZ P, et al: Clinical evaluation
of heme iron polypeptide: Sustaining a response to rHuEPO in
hemodialysis patients. Am J Kidney Dis 42:325–330, 2003
